NO20030856D0 - Membranpenetrerende peptider og anvendelse av disse - Google Patents

Membranpenetrerende peptider og anvendelse av disse

Info

Publication number
NO20030856D0
NO20030856D0 NO20030856A NO20030856A NO20030856D0 NO 20030856 D0 NO20030856 D0 NO 20030856D0 NO 20030856 A NO20030856 A NO 20030856A NO 20030856 A NO20030856 A NO 20030856A NO 20030856 D0 NO20030856 D0 NO 20030856D0
Authority
NO
Norway
Prior art keywords
penetrating peptides
membrane penetrating
interest
vivo
cells
Prior art date
Application number
NO20030856A
Other languages
English (en)
Other versions
NO20030856L (no
NO332050B1 (no
Inventor
Yong Guo
Clarence C Morse
Zhengbin Yao
Jr George A Keesler
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0103110.3A external-priority patent/GB0103110D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NO20030856D0 publication Critical patent/NO20030856D0/no
Publication of NO20030856L publication Critical patent/NO20030856L/no
Publication of NO332050B1 publication Critical patent/NO332050B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
NO20030856A 2000-08-25 2003-02-24 Fusjonsprotein for avlevering av et organisk molekyl inn i en celle NO332050B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
PCT/US2001/026421 WO2002018572A2 (en) 2000-08-25 2001-08-23 Membrane penetrating peptides and uses thereof

Publications (3)

Publication Number Publication Date
NO20030856D0 true NO20030856D0 (no) 2003-02-24
NO20030856L NO20030856L (no) 2003-04-24
NO332050B1 NO332050B1 (no) 2012-06-11

Family

ID=26245698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030856A NO332050B1 (no) 2000-08-25 2003-02-24 Fusjonsprotein for avlevering av et organisk molekyl inn i en celle

Country Status (9)

Country Link
EP (1) EP1360311B1 (no)
AT (1) ATE391791T1 (no)
AU (1) AU8524901A (no)
CA (1) CA2420350C (no)
IL (1) IL154589A0 (no)
MX (1) MXPA03001622A (no)
NO (1) NO332050B1 (no)
NZ (1) NZ524386A (no)
WO (1) WO2002018572A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086927A1 (en) 1995-11-01 2003-05-08 University Of Southern California Expression of cyclin G1 in tumors
CA2285937C (en) 1997-04-10 2010-12-14 Frederick L. Hall Modified proteins which bind extracellular matrix components
FR2781674B1 (fr) * 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
EP1146869A2 (en) 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
AU2003209370A1 (en) * 2002-01-23 2003-09-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of New tumor suppressor gene, p28ing5
EP1496927A4 (en) * 2002-01-29 2007-09-12 Aventis Pasteur IMMUNOGENES TARGETS
KR20030078115A (ko) * 2002-03-28 2003-10-08 (주)코아바이오텍 펩타이드 유전자 전달매체 및 이를 이용한 유전자 전달 방법
DE60329089D1 (de) * 2002-03-29 2009-10-15 Creagene Inc Zytoplasmatische transduktionspeptide und deren verwendungen
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
WO2005066203A2 (en) * 2003-12-31 2005-07-21 Sanofi Pasteur, Inc. Targeted immunogens
EP1950294B1 (en) 2005-10-28 2012-01-18 Mitsubishi Tanabe Pharma Corporation Novel cell penetrating peptide
EP1976869A2 (en) * 2005-12-23 2008-10-08 Partnership&Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
AU2009215426B2 (en) 2008-02-21 2015-06-11 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with C-terminal elements
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
US10370245B2 (en) 2009-06-22 2019-08-06 Sanford-Burnham Medical Research Institute Methods and compositions using peptides and proteins with C-terminal elements
WO2011013699A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメントとその利用
JP5858285B2 (ja) 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
EP2497784B1 (en) 2009-11-02 2016-01-06 Toagosei Co., Ltd Peptide capable of promoting cell proliferation, and use thereof
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
WO2014061749A1 (ja) 2012-10-18 2014-04-24 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
KR101671114B1 (ko) 2015-06-26 2016-10-31 충북대학교 산학협력단 Ｕｌｋ２로부터 유래된 핵 위치화 신호 펩타이드 및 이의 용도
CN117940135A (zh) * 2021-08-06 2024-04-26 宾夕法尼亚大学理事会 用于治疗和预防错误折叠的蛋白的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
WO1998049325A1 (en) * 1997-04-28 1998-11-05 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
JP2003514564A (ja) * 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
CA2411542A1 (en) * 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes

Also Published As

Publication number Publication date
WO2002018572A2 (en) 2002-03-07
EP1360311B1 (en) 2008-04-09
IL154589A0 (en) 2003-09-17
CA2420350A1 (en) 2002-03-07
CA2420350C (en) 2010-07-13
MXPA03001622A (es) 2004-09-06
NO20030856L (no) 2003-04-24
WO2002018572A3 (en) 2003-09-12
NO332050B1 (no) 2012-06-11
ATE391791T1 (de) 2008-04-15
AU8524901A (en) 2002-03-13
EP1360311A2 (en) 2003-11-12
NZ524386A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
NO20030856L (no) Membranpenetrerende peptider og anvendelse av disse
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60144145D1 (de) Subtilisin-variante
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR0312764A (pt) Cardiomiócitos funcionais originados de células-tronco embrionárias humanas
EP1401869A4 (en) MOLECULES AND METHODS FOR PREVENTING KIM-1 RELEASE
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
NO20032286D0 (no) Anvendelse av CLyA-hemolysin for utskillelse av proteiner
RS51478B (sr) Upotreba bradikardijskih supstanci u lečenju miokardnih oboljenja povezanih sa hipertrofijom i nove kombinacije lekova
NO20031860D0 (no) Kahalaolid F
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
YU90301A (sh) Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane
CY1109815T1 (el) Μεθοδοι διασταυρουμενης συμβατοτητας ειδικες δοτη
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
SE0103765D0 (sv) New use
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
DK1230261T3 (da) NY-ESO-1 Nonapeptidderivater og anvendelser af disse
BR0316544A (pt) Compostos calcilìticos
HK1076735A1 (en) Antigen-specific ige antibody production inhibitors
ATE348176T1 (de) Komplex aus peptid und mhc-peptid auf oberfläche von phagen
ATE466077T1 (de) Eine metacaspasen-klasse
SE0202608D0 (sv) New sequences

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AVENTISUB LLC, US

MK1K Patent expired